Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib Maintenance for FLT3-ITD AML Post-Transplant
NCT02474290Phase 3Completed
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sorafenib in acute myeloid leukemia (AML), sponsored by Nanfang Hospital, Southern Medical University. Started Jun 2015; status: completed.
02
Drugs
sorafenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02474290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02474290.